Our very virst patient has been enrolled in the IBIS study!

This study explores the use of iberdomide, isatuximab, and dexamethasone triplet in treating functional high-risk MM patients (patients who relapse within the first 12 months of starting first line therapy). 

Click here for more information, or e-mail us at amarc@alfred.org.au.